Aptose Biosciences Inc. (NASDAQ:APTO) Given Average Rating of “Buy” by Analysts

Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) have been assigned an average recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have covered the stock in the last year is $14.83.

APTO has been the topic of a number of research reports. Canaccord Genuity Group reduced their price objective on Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, May 16th. StockNews.com began coverage on Aptose Biosciences in a research note on Wednesday, July 24th. They issued a “hold” rating for the company. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Aptose Biosciences in a research report on Friday, June 14th. Finally, Piper Sandler restated an “overweight” rating and issued a $5.00 price target on shares of Aptose Biosciences in a research report on Wednesday, April 3rd.

Aptose Biosciences Stock Performance

APTO opened at $0.57 on Friday. The company has a market cap of $10.31 million, a P/E ratio of -0.09 and a beta of 1.27. The company’s 50 day moving average is $0.82 and its 200-day moving average is $1.34. Aptose Biosciences has a 1-year low of $0.55 and a 1-year high of $5.10.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.09. On average, equities analysts forecast that Aptose Biosciences will post -2.62 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned about 0.16% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.